Previous studies have found that common AEs associated with the “trastuzumab + pertuzumab” neoadjuvant regimen, including neutropenia, diarrhea, nausea, vomiting, anemia, and increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels [28]. Here, GPT is linked to anemia.